Coherus BioSciences has announced promising results from its ongoing Phase 1 clinical trial of CHS-114, a selective anti-CCR8 antibody, in combination with toripalimab for patients with recurrent ...

CHS-114, targeting CCR8+ Tregs, showed promising results in head and neck squamous cell carcinoma by enhancing CD8+ T cells and remodeling the tumor microenvironment. Micvotabart pelidotin ...

(RTTNews) - Coherus BioSciences, Inc. (CHRS), Monday announced data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in ...